{"prompt": "['NET-PRO Protocol v1.3', 'April 2022', 'Abbreviations', 'Abbreviation', 'Meaning', 'BRE', 'Business Reply Envelope', 'CDM', 'Common Data Model', 'CER', 'Comparative Effectiveness Research', 'CgA', 'Chromogranin A', 'CRNs', 'Clinical Research Networks', 'EMR', 'Electronic Medical Record', 'EORTO', 'European Organization for Research and Treatment of Cancer', 'FDA', 'Federal Drug Administration', 'G1/G2/G3', 'Grade 1, 2, 3 tumors', 'GEP', 'Gastroenteropancreatic', 'GFR', 'Glomerular Filtration Rate', 'HRQoL', 'Health-related Quality of Life', 'IRB', 'Institutional Review Board', 'MCID', 'Minimal Clinical Important Difference', 'mTOR', 'Mammalian target of rapamycin', 'NAACCR', 'North American Association of Central Cancer Registries', 'NECs', 'Neuroendocrine carcinomas', 'NET-PRO', 'Neuroendocrine Tumors - Patient Reported Outcomes (Study Title)', 'NETs', 'Neuroendocrine tumors', 'os', 'Overall survival', 'PAC', 'Patient Advocacy Committee', 'PCORI', 'Patient Centered Outcomes Research Institute', 'PCORnet', 'Patient Centered Outcomes Research Network', 'PFS', 'Progression Free Survival', 'PHI', 'Patient Health Information', 'PHR', 'Personal Health Record research portal (i.e.: Study Web Portal)', 'PI', 'Principal Investigator', 'PPV', 'Positive Predictive Value', 'PROs', 'Patient Reported Outcomes', 'PRRT', 'Peptide Receptor Radionuclide Therapy', 'SEER', 'Surveillance Epidemiology End Results', 'SSAs', 'Somatostatin analogues', 'TDPS', 'Time Dependent Propensity Score', 'UICC', 'University of lowa Coordinating Center', 'WHO', 'World Health Organization', '3']['NET-PRO Protocol v1.3', 'April 2022', 'Table of Contents', 'Contents', 'Protocol Version and Amendment Tracking', '2', 'Abbreviations', '3', 'Table of Contents', '4', 'PROTOCOL SYNOPSIS', '8', '1.', 'INTRODUCTION', '10', '1.1.', 'Background', '10', '1.1.1.', 'Health related quality of life impact of NETs', '10', '1.1.2.', 'Nomenclature of NETs', '10', '1.1.3.', 'Gaps in Optimal therapy selection and sequencing', '11', '1.1.4.', 'Important NET subgroups', '13', '1.1.5.', 'Significance', '13', '1.1.6.', 'Potential to advance rare disease research using PCORnet', '14', '2.', 'SPECIFIC AIMS', '15', '2.1.', 'Purpose', '15', '3.', 'STUDY OVERVIEW', '17', '3.1.', 'Overview and approach', '17', '3.2.', 'Setting', '17', '4.', 'STUDY DESIGN', '19', '4.1.', 'Time anchors for study cohort', '19', '4.2.', 'Inclusion/Exclusion Criteria', '19', '4.3.', 'Cohort Identification and Selection', '19', '4.3.1.', 'Potential modes of subject identification', '19', '4.4.', 'Development of a NET Computable Phenotype', '19', '5.', 'RECRUITMENT, ENROLLMENT AND STUDY ACTIVITIES', '21', '5.1.', 'Overview', '21', '5.2.', 'Roles and responsibilities of enrolling sites and UICC', '21', '5.2.1.', 'University of Iowa Coordinating Center (UICC) roles and responsibilities', '21', '5.2.2.', 'Enrolling site roles and responsibilities', '21', '5.3.', 'Identifying patients for recruitment at participating sites', '22', '5.3.1.', 'Data elements used to identify potential subjects for recruitment', '22', '5.4.', 'Assigning and maintaining unique IDs and PHR credential linkage to patients', '22', '5.5.', 'Patient recruitment and recruitment materials - initial contacts', '22', '5.5.1.', 'E-mail', '23', '4']\n\n###\n\n", "completion": "END"}